Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 1, 2008

Peregrine to Investigate Antiviral Applications of mAbs under $44M Deal with DoD

  • Peregrine Pharmaceuticals was awarded a five-year contract by the DoD worth up to $44.4 million related to treatments for viral hemorrhagic fever infections. The firm will test and develop bavituximab and an equivalent fully human antibody.

    Under the terms of the contact, Peregrine will recieve $5 million immediately. Over a 24-month base period, the company will have access to another $17.3 million for testing and development efforts. The contract can be extended beyond the base period to cover up to $44.4 million in funding over the five-year contract.

    Bavituximab is the firm’s lead antiphosphatidylserine (anti-PS) mAb. It is currently in Phase I trials for HCV. The fully human anti-PS antibody to be assessed under this contract is currently in preclinical development.

    The contract was awarded through the Transformational Medical Technologies Initiative of the DOD’s Defense Threat Reduction Agency (DTRA).



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »